Dupont Capital Management Corp Grows Stake in Zoetis Inc. (NYSE:ZTS)

Dupont Capital Management Corp raised its stake in Zoetis Inc. (NYSE:ZTS) by 28.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,190 shares of the company’s stock after purchasing an additional 8,596 shares during the quarter. Dupont Capital Management Corp’s holdings in Zoetis were worth $7,657,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in ZTS. Webster Bank N. A. increased its position in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the last quarter. Quarry LP increased its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the last quarter. LRI Investments LLC purchased a new stake in shares of Zoetis during the first quarter worth about $43,000. Central Valley Advisors LLC purchased a new stake in shares of Zoetis during the second quarter worth about $49,000. Finally, Future Financial Wealth Managment LLC purchased a new stake in shares of Zoetis during the first quarter worth about $51,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ZTS. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Stock Performance

Shares of ZTS stock opened at $189.52 on Wednesday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The business has a 50 day moving average of $189.11 and a two-hundred day moving average of $177.50. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a market cap of $86.48 billion, a P/E ratio of 36.52, a PEG ratio of 3.00 and a beta of 0.89.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the firm posted $1.41 earnings per share. Zoetis’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, analysts anticipate that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.91%. Zoetis’s dividend payout ratio (DPR) is presently 33.14%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.